Rigel Pharmaceuticals, Inc.
RIGLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Rigel Pharmaceuticals, Inc. (RIGL) is listed under Biotechnology. Valued at $890.5M, RIGL is a small-cap name in its sector. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
Market Cap
$890.5M
Beta
1.19
P/E (TTM)
2.89
P/E (Fwd)
9.74
EPS (TTM)
$16.63
EPS (Fwd)
$4.94
ROE
126.9%
ROA
14.9%
Cash
$95.3M
Total Debt
$40.0M
Free CF
-$31.8M
52W Change
60.6%
Annual Financials
Cash vs Debt
Where RIGL stands vs its 150-day and 200-day moving averages
As of the October 5, 2026 close, RIGL finished 31.19% above its 150-day moving average ($35.94) and 29.04% above its 200-day moving average ($36.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RIGL overbought or oversold?
At the October 5, 2026 close, RIGL's RSI(14) was 58.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $95.3M in cash and $40.0M in debt, RIGL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$31.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 126.9% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 14.9% further supports the picture of efficient asset utilization. Revenue has grown from $120.2M (2022) to $294.3M (2025), reflecting a 145% increase over the period.
With cash comfortably exceeding debt, RIGL has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RIGL.